Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nissan Medical Industries Ltd (NISA) Fair Value & Analysis

Healthcare · Il · Market cap 62.7M ILA

Price7.42 ILA
Fair Value13.62 ILA
Upside+83.6%
Quality80/100
Evidence: Medium Range 13.62 ILA – 21.55 ILA

Fair value as of: Jun 24, 2026

Analysis

Nissan Medical Industries Ltd (NISA) currently trades at 7.42 ILA, while our model-based Fair Value estimate is 13.62 ILA — implying the stock looks roughly 83.6% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Nissan Medical Industries Ltd manufactures and markets spunlace non-woven fabrics in the United States, Canada, Europe, the Far East, Israel, and internationally. Its products are used in reusable and consumable consumer products, medical products, automotive, infrastructure, hygienic, and other industries. The company sells its products through its sales agents. Nissan Medical Industries Ltd was incorporated in 1984 and is based in Tel Aviv-Yafo, Israel.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44%

Frequently asked questions

Is Nissan Medical Industries Ltd (NISA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 13.62 ILA versus a price of 7.42 ILA — about +84% (undervalued). Model-based estimate, not financial advice.
What is the fair value of NISA?
Our 21-model fair value for Nissan Medical Industries Ltd is 13.62 ILA (as of Jun 24, 2026), built from audited fundamentals. The current price is 7.42 ILA.
What is the quality score of NISA?
Nissan Medical Industries Ltd has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.